Study on Quercetin for Preventing Squamous Cell Carcinoma in Patients with Fanconi Anemia

Program Overview

Fanconi Anemia is a genetic condition that can lead to bone marrow failure and increase the risk of certain cancers, like squamous cell carcinoma (SCC). This study is testing if quercetin, a natural substance, can help prevent or delay SCC in people with Fanconi Anemia. By doing so, it might reduce the need for treatments like chemotherapy or radiation, which can have serious side effects. The study is funded by the FDA's Office of Orphan Products Development.

Description

This study focuses on people with Fanconi Anemia, a genetic disorder that can cause bone marrow problems and increase the risk of cancers like squamous cell carcinoma (SCC). The only current cure for the blood-related issues in Fanconi Anemia is a bone marrow transplant. Researchers believe that quercetin, a natural compound, might help prevent or delay SCC and its complications, potentially reducing the need for harsh treatments like chemotherapy or radiation.

The study is open-label, meaning all participants will know they are receiving quercetin. It will include about 45 patients who have had a bone marrow transplant and about 10 who have not. Participants can join whether or not they have had SCC or pre-cancerous lesions, as long as they meet the study criteria and the lead researcher agrees. All participants will take quercetin by mouth.

Researchers will look at how well quercetin works by measuring changes in buccal micronuclei, which are indicators of DNA damage and cancer risk, in patients with Fanconi Anemia who have had a transplant.

Eligibility Criteria